WHITEHAWK THERAPEUTICS INC (WHWK)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.21-1.23%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge WHITEHAWK THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.203
Annual ending 2026-12-31
Revenue	—	8.83M
EPS	—	-0.921
Annual ending 2027-12-31
Revenue	—	10.91M
EPS	—	-0.871

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage capital through financing and M&A	A supporting condition in WHITEHAWK THERAPEUTICS INC's published investment case. The stated target is Maintain access to capital and complete strategic deals next 12 months.	Intact	Failure to secure capital or complete deals within next 12 months	Qualitative: Capital secured via May 2026 PIPE May 2026 PIPE deal with investors at $3.92/share confirms capital access; no evidence of stalled recovery or deal failure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce losses and improve earnings	A primary condition in WHITEHAWK THERAPEUTICS INC's published investment case. The stated target is EPS loss narrows toward 0 next 4 quarters.	Improving	EPS remains below -1.0 USD per share next 4 quarters	Diluted EPS: $-0.20 per share FY2026-Q2; GAAP. Published target: EPS loss narrows toward 0 next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.2 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b310a342-7874-45f6-8a4e-c7d49c365953. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Sustain revenue generation efforts	A primary condition in WHITEHAWK THERAPEUTICS INC's published investment case. The stated target is >0 USD millions revenue next 4 quarters.	Intact	revenue remains at or below 0 USD millions next 4 quarters	Revenue: $0 FY2026-Q2; GAAP. Published target: >0 USD millions revenue next 4 quarters. Target period is not explicitly aligned with this observation. Source published Jun 30, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue declined from $7.1 million in 2025-Q1 to zero in 2026-Q2, indicating limited progress in revenue generation. Management continues to emphasize revenue efforts but financials show stagnant to declining revenue. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.87

Unavailable → $-0.87 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$10,908,447	4 / 5
2026-07-25	Unavailable	$-1,142,860	4 / 7
2026-07-26	Unavailable	$-1,142,860	4 / 7
2026-07-27	Unavailable	$10,908,447	4 / 5
2026-07-28	Unavailable	$-1,142,860	4 / 7
2026-07-29	Unavailable	$10,908,447	4 / 5
2026-07-30	Unavailable	$-1,142,860	4 / 7
2026-07-31	Unavailable	$-1,142,860	4 / 7
2026-08-01	Unavailable	Unavailable	4 / 2
2026-08-02	Unavailable	Unavailable	4 / 2
2026-08-03	Unavailable	$-1,142,860	4 / 7
2026-08-04	Unavailable	Unavailable	4 / 2
2026-08-05	Unavailable	Unavailable	4 / 2
2026-08-06	Unavailable	$-1,142,860	4 / 7
2026-08-08	Unavailable	Unavailable	4 / 2
2026-08-09	Unavailable	Unavailable	4 / 2
2026-08-10	Unavailable	Unavailable	4 / 2
2026-08-12	Unavailable	Unavailable	4 / 2
2026-08-13	Unavailable	$0	3 / 7
2026-08-14	Unavailable	Unavailable	4 / 2
2026-08-15	Unavailable	Unavailable	4 / 2
2026-08-16	Unavailable	Unavailable	4 / 2
2026-08-17	Unavailable	Unavailable	4 / 2
2026-08-18	Unavailable	Unavailable	4 / 2
2026-08-19	Unavailable	Unavailable	4 / 2
2026-08-20	Unavailable	$10,908,447	4 / 7
2026-08-21	Unavailable	$10,908,447	4 / 7
2026-08-22	Unavailable	$10,908,447	4 / 7
2026-08-23	Unavailable	$10,908,447	4 / 7
2026-08-24	Unavailable	$10,908,447	4 / 7
2026-08-25	Unavailable	$10,908,447	4 / 7
2026-08-26	Unavailable	$10,908,447	4 / 7
2026-08-27	Unavailable	$10,908,447	4 / 7
2026-08-28	Unavailable	$10,908,447	4 / 7
2026-08-29	Unavailable	$10,908,447	4 / 7
2026-08-30	Unavailable	$10,908,447	4 / 7
2026-08-31	Unavailable	$10,908,447	4 / 7
2026-09-01	Unavailable	$10,908,447	4 / 7
2026-09-02	Unavailable	$10,908,447	4 / 7
2026-09-03	Unavailable	$10,908,447	4 / 7
2026-09-04	Unavailable	$10,908,447	4 / 7
2026-09-05	Unavailable	$10,908,447	4 / 7
2026-09-06	Unavailable	$10,908,447	4 / 7
2026-09-07	Unavailable	$10,908,447	4 / 7
2026-09-08	Unavailable	$10,908,447	4 / 7
2026-09-09	Unavailable	$10,908,447	4 / 7
2026-09-10	Unavailable	$10,908,447	4 / 7
2026-09-11	Unavailable	$10,908,447	4 / 7
2026-09-12	Unavailable	$10,908,447	4 / 7
2026-09-13	Unavailable	$10,908,447	4 / 7
2026-09-14	Unavailable	$10,908,447	4 / 7
2026-09-15	Unavailable	$10,908,447	4 / 7
2026-09-16	Unavailable	$10,908,447	4 / 7
2026-09-17	Unavailable	$10,908,447	4 / 7
2026-09-18	Unavailable	$10,908,447	4 / 7
2026-09-19	Unavailable	$10,908,447	4 / 7
2026-09-20	Unavailable	$10,908,447	4 / 7
2026-09-21	Unavailable	$10,908,447	4 / 7
2026-09-22	Unavailable	$10,908,447	4 / 7
2026-09-23	Unavailable	$10,908,447	4 / 7
2026-09-24	Unavailable	$10,908,447	4 / 7
2026-09-25	Unavailable	$10,908,447	4 / 7
2026-09-26	Unavailable	$10,908,447	4 / 7
2026-09-27	Unavailable	$10,908,447	4 / 7
2026-09-28	Unavailable	$10,908,447	4 / 7
2026-09-29	Unavailable	$10,908,447	4 / 7
2026-09-30	Unavailable	$10,908,447	4 / 7
2026-10-01	Unavailable	$10,908,447	4 / 7
2026-10-02	Unavailable	$10,908,447	4 / 7
2026-10-03	$-0.89	$10,908,447	5 / 8
2026-10-04	$-0.89	$10,908,447	5 / 8
2026-10-05	$-0.89	$10,908,447	5 / 8
2026-10-06	$-0.89	$10,908,447	5 / 8
2026-10-07	$-0.89	$10,908,447	5 / 8
2026-10-08	$-0.89	$10,908,447	5 / 8
2026-10-09	$-0.89	$10,908,447	5 / 8
2026-10-10	$-0.89	$10,908,447	5 / 8
2026-10-11	$-0.89	$10,908,447	5 / 8
2026-10-12	$-0.89	$10,908,447	5 / 8
2026-10-13	$-0.89	$10,908,447	5 / 8
2026-10-14	$-0.89	$10,908,447	5 / 8
2026-10-15	$-0.89	$10,908,447	5 / 8
2026-10-16	$-0.89	$10,908,447	5 / 8
2026-10-17	$-0.89	$10,908,447	5 / 8
2026-10-18	$-0.89	$10,908,447	5 / 8
2026-10-19	$-0.89	$10,908,447	5 / 8
2026-10-20	$-0.89	$10,908,447	5 / 8
2026-10-21	$-0.89	$10,908,447	5 / 8
2026-10-22	$-0.89	$10,908,447	5 / 8
2026-10-23	$-0.89	$10,908,447	5 / 8
2026-10-24	$-0.87	$10,908,447	5 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	3
2026-06-01	4	3
2026-07-01	5	3
2026-08-01	5	3
2026-09-01	5	3
2026-10-01	6	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Stifel NicolausSep 30

$9.00New observation · no comparable prior

$0$4.95$9.90

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce losses and improve earningsDiluted EPS: $-0.20 per share
Sustain revenue generation effortsRevenue: $0

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-43.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

WHITEHAWK THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

WHWK is a speculative clinical-stage healthcare business, with progress tied to drug development rather than established profits. Its long-term thesis is on watch: management is advancing stated priorities, but recent performance is below its industry cohort and the risk label has risen to high.

What's priced into WHITEHAWK THERAPEUTICS INC

The valuation evidence describes WHWK as cheap versus peers, with medium confidence in that comparison. The priced-in evidence says only weak execution quality is reflected, not the full combination of expensive valuation, weak execution, and turbulence. This suggests the market may not be fully accounting for the business’s risks.

What the fundamentals likely do

Near term, the next results carry meaningful execution risk; the evidence gives a 41% miss probability and notes a high-miss-rate industry and smaller-company size. Management has extended cash runway into the second half of 2028 and is progressing clinical programs, with initial data expected in the first half of 2027. Results remain mixed overall, and the recent earnings beat is balanced by performance below the industry cohort.

What WHITEHAWK THERAPEUTICS INC hinges on

The multi-year thesis hinges on whether clinical programs deliver useful data and whether WHWK can sustain its cash runway while advancing them. A guidance cut or further weakening in jobs data would add pressure, while continued strong results and guidance from healthcare peers could support sector momentum.